PSNL's Quality Score fell 1 point on Tue, Nov 10, to 5. It closed away from its high of the day.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 1,597% over three years while the S&P 500 rose 80%.
“Total revenue of $25.6 million compared with $14.5 million, primarily driven by growth in clinical test revenue”
| Holding it back | A $119M loss |
| Latest filing | 8-K, Nov 4 |
Mon Nov 30: Special Shareholder MeetingDate confirmed.
After its last 4 reports it closed -0.3% on average, higher 1 of 4 times.
Below Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
PSNL is #13 of 18 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 13 |
Expected to report Thu Feb 25, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $25.6M, 77% more than a year ago; a loss of $0.32 a share, from $0.24.
“Total revenue of $25.6 million compared with $14.5 million, primarily driven by growth in clinical test revenue, as well as core revenue from increased population sequencing and higher pharma testing services.”
PSNL's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Clinical test revenue of $4.4 million compared with $0.4 million, resulting from the increase in test volume and also a full quarter of Medicare covered IO test volume, in addition to revenue from breast and lung cancer covered tests; delivered 13,157 clinical tests compared with 4,388.”
From its results filing (SEC filing · Nov 4)
Sales fell 2.4% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 12% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -0.2% | -1.5% | not yet |
| Aug 4, 2026 | -0.6% | 0.0% | +3.7% |
| May 7, 2026 | -4.8% | -0.2% | +12.0% |
Sales grew in five of the last seven years, to $69.6M in 2025. It lost money in each of the eight years.
RSI 49.6, MACD above signal, below its 50-day, above its 200-day. Not scored.
4 insiders sold $729K across 5 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PSNL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
“Our principal competition comes from commercial and academic organizations that employ various approaches to produce test results or information that is similar to what we generate for our patients and customers.”
PSNL scores 5 today, which Breakaway calls Below Average. It is #13 of 18 in Services-Medical Laboratories by Quality Score, with 5 of 14 chart checks firing. Up 1,597% over three years while the S&P 500 rose 80%. Shares: 20.9% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PSNL scores 5 today, which Breakaway calls Below Average (0 to 5). That is #13 of 18 in Services-Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PSNL's 5.
4 insiders sold $729K across 5 filings in the last 6 months. No open-market buys on record. The newest is Christopher M. Hall, Chief Executive Officer, who sold $462K on Nov 3. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.